CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 23, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34 th Annual Healthcare Conference on Thursday,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 22, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 ,

Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022 Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD Company appoints Laura

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault , MD, Ph.D. as Chief Medical Officer. In her new role, Dr.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November 8, 2022 at 8:00 a.m.

Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 19, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday,

Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology